NYSE · HIMS
Healthcare · Medical - Equipment & Services
$28.44
Up+$0.24 (+0.84%)
Updated Sep 2, 2026, 9:02 PM
SID Score
4.3/10
Composite research score
Smart Money
60/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
HIMS closed at $28.44 after 21 trading sessions, down 11.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $29.28 | $29.87 | $28.38 | $28.44 | 7.3M |
| Aug 31, 2026 | $28.67 | $29.7898 | $28.63 | $29.58 | 8.31M |
| Aug 28, 2026 | $31.36 | $31.40 | $28.52 | $28.84 | 14.73M |
| Aug 27, 2026 | $30.40 | $31.985 | $29.7244 | $31.66 | 9.62M |
| Aug 26, 2026 | $31.04 | $31.6295 | $29.62 | $29.83 | 11.58M |
| Aug 25, 2026 | $31.29 | $32.51 | $30.73 | $31.75 | 9.64M |
| Aug 24, 2026 | $32.44 | $32.72 | $30.30 | $31.08 | 13.87M |
| Aug 21, 2026 | $31.67 | $34.4556 | $31.60 | $33.78 | 14.71M |
| Aug 20, 2026 | $30.66 | $33.16 | $30.66 | $31.86 | 18.93M |
| Aug 19, 2026 | $27.55 | $31.27 | $27.41 | $31.09 | 20.01M |
| Aug 18, 2026 | $27.85 | $28.85 | $27.38 | $27.39 | 7.93M |
| Aug 17, 2026 | $28.14 | $28.73 | $27.51 | $28.61 | 10.35M |
| Aug 14, 2026 | $29.15 | $29.30 | $28.105 | $28.15 | 9.03M |
| Aug 13, 2026 | $29.74 | $30.10 | $28.54 | $28.77 | 12.72M |
| Aug 12, 2026 | $30.475 | $30.9899 | $29.25 | $29.97 | 16.91M |
| Aug 11, 2026 | $29.71 | $31.79 | $29.41 | $30.51 | 23.17M |
| Aug 10, 2026 | $31.07 | $32.29 | $30.90 | $31.77 | 17.69M |
| Aug 7, 2026 | $30.19 | $31.72 | $29.80 | $31.59 | 8.39M |
| Aug 6, 2026 | $31.11 | $31.26 | $29.53 | $29.66 | 8.29M |
| Aug 5, 2026 | $31.59 | $32.415 | $31.1305 | $31.65 | 8.38M |
| Aug 4, 2026 | $31.09 | $32.31 | $30.77 | $32.16 | 11.43M |
The latest Smart Investors Daily articles mentioning HIMS.
HIMS research
Company profile and research snapshot.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Truist Securities | Hold | — |
| Aug 21, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| Aug 11, 2026 | B of A Securities | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Aug 27, 2026
Hims & Hers approaches 3 million subscribers as U.S. growth reaccelerates and international markets emerge as a meaningful second growth engine. Learn more about HIMS stock here.
Benzinga · Aug 24, 2026
Truist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.
Yahoo · Aug 22, 2026
Hims & Hers Health (HIMS) stock is back in focus after the Federal Trade Commission and state regulators filed a civil enforcement action, followed by a consumer class action targeting the company’s telehealth privacy and subscription practices. See our latest analysis for Hims & Hers Health. The latest 1-day share price return of 6.03% and 7-day return of 20.00% put Hims & Hers Health back in sharp focus. However, the 1-year total shareholder return is down 24.21%, while the 3-year total...
Yahoo · Aug 21, 2026
Hims & Hers Health (HIMS) was placed on notice by Visa for excessive customer complaints in its weig
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HIMS.
